PI
BCRX icon

PEAK6 Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

PEAK6 Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$532K Hold
70,000
– – ﹤0.01% 2278
2024
Q2 		$433K Buy
+70,000
New +$386K ﹤0.01% 2327

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

PEAK6 Investments's BCRX Position: Q3 2024 in Review

PEAK6 Investments held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2024 at 70,000 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

PEAK6 Investments first reported a position in BCRX in Q2 2024 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • PEAK6 Investments held 70,000 shares of BioCryst Pharmaceuticals worth $532K as of Q3 2024.
  • PEAK6 Investments left its BioCryst Pharmaceuticals share count unchanged in Q3 2024.
  • BioCryst Pharmaceuticals made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2278 holding.
  • PEAK6 Investments first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.